Latest Article on Diabetes
![The future of diabetes Prof. Lalic and Marino Fernandez](/sites/default/files/Prescription_Medicine/metabolic_diseases/diabetes_metabolic_diseases_prescription_medicine/The%20future%20of%20diabetes.png)
The Future of Diabetes
![Conversations Beyond Type 2 Diabetes Franc and Anne](/sites/default/files/Prescription_Medicine/metabolic_diseases/diabetes_metabolic_diseases_prescription_medicine/Conversations%20Beyond%20Type%202%20Diabetes.png)
Conversations Beyond Type 2 Diabetes
![EFPIA Mission Possible EFPIA Mission Possible](/sites/default/files/Prescription_Medicine/metabolic_diseases/diabetes_metabolic_diseases_prescription_medicine/EFPIA_hero_card.png)
EFPIA Mission Possible
![](/sites/default/files/Images/press-release-holding-image02.jpg)
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status
![](/sites/default/files/Images/press-release-holding-image01.jpg)
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes
Links
Heart Talks
Heart Failure Matters
Downloads
Diabetic Retinopathy
Harold and Dorothy Patient Discussion Factsheet
Type 2 Diabetes
1 Diabetes Atlas 8th edition 2017, International Diabetes Federation. http://www.diabetesatlas.org (accessed Jan 2019)